Research programme: cancer biotherapeutics - Zymeworks

Drug Profile

Research programme: cancer biotherapeutics - Zymeworks

Alternative Names: Bispecific ADCs - Zymeworks; Checkpoint Modulating Bispecifics - Zymeworks; T Cell Engaging Bispecifics - Zymeworks

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates
  • Mechanism of Action Immunomodulators; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 Jun 2017 Preclinical trials in Solid tumours in Canada (Parenteral) before June 2017 (Zymeworks pipeline, June 2017)
  • 22 Mar 2016 Kairos Therapeutics has been acquired by Zymeworks
  • 08 Jan 2016 Kairos Therapeutics and Zymeworks enter into an agreement to develop Cancer biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top